NasdaqGM:MIRMBiotechs
Mirum Pharmaceuticals (MIRM) Is Down 12.8% After Shelf Filing For US$1.3 Billion Equity Issuance
In late February 2026, Mirum Pharmaceuticals reported Q4 2025 revenue of US$148.93 million and a quarterly net loss of US$5.73 million, alongside filing shelf registrations to potentially issue up to 12,074,780 new common shares worth about US$1.30 billion.
While these results showed a smaller annual net loss of US$23.36 million on full-year revenue of US$521.31 million, the large prospective equity issuance raised fresh questions about dilution and how Mirum plans to finance its ongoing...